Conservative
Lower growth, cautious assumptions
Annual Revenue
$2,911,248
EBITDA Margin
73.86%
Break-even Month
Month 1
Key Assumptions
- Patients/month: 30
- Growth rate: 2%
- Ablation: $2,200
- Marketing: $12,000/mo
Baseline
Realistic, achievable projections
Annual Revenue
$9,274,290
EBITDA Margin
88.85%
Break-even Month
Month 1
Key Assumptions
- Patients/month: 50
- Growth rate: 5%
- Ablation: $2,500
- Marketing: $10,000/mo
Aggressive
High growth, optimistic scenario
Annual Revenue
$26,066,421
EBITDA Margin
94.67%
Break-even Month
Month 1
Key Assumptions
- Patients/month: 75
- Growth rate: 8%
- Ablation: $2,800
- Marketing: $8,000/mo
Side-by-Side Comparison
| Metric | Conservative | Baseline | Aggressive |
|---|---|---|---|
| First Year Revenue | $2,295,499 | $5,164,272 | $10,351,335 |
| Annual Revenue (Year 2) | $2,911,248 | $9,274,290 | $26,066,421 |
| First Year EBITDA | $1,695,499 | $4,588,272 | $9,799,335 |
| Annual EBITDA (Year 2) | $2,311,248 | $8,698,290 | $25,514,421 |
| EBITDA Margin | 73.86% | 88.85% | 94.67% |
| Break-even Month | Month 1 | Month 1 | Month 1 |
| Valuation (6x EBITDA) | $13,867,488 | $52,189,740 | $153,086,526 |
Conservative Use Case
Best for risk-averse planning and worst-case scenario preparation. Assumes slower market penetration, lower reimbursement rates, and higher marketing costs to acquire patients.
Baseline Use Case
Most likely scenario based on industry benchmarks and realistic market conditions. Represents achievable targets with proper execution and standard market conditions.
Aggressive Use Case
Optimistic scenario assuming strong market demand, excellent referral network development, and favorable reimbursement environment. Requires excellent execution.